You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Byetta Articles
Popular Byetta Articles
Highly Recommended Byetta Articles
Send a link to this page to your friends and colleagues.
The stock of Byetta manufacturer Amylin Pharmaceuticals has lost more than half of its value over the past eight weeks, thanks to FDA concerns that the type 2 treatment may be connected with the deaths from acute pancreatitis of six Byetta users. Although the FDA has not proven a direct association between fatal pancreatitis and the use of Byetta, Amylin's stock has fallen nevertheless.
Adding to the company's problems is speculation among financial analysts that the FDA may delay until 2011 its approval of a long-acting form of Byetta called exenatide LAR. Amylin had hoped to receive approval by 2010 by the latest.
The long-acting form, which is administered by injection once a week, is now undergoing testing under FDA auspices. Current Byetta users inject the drug twice daily, usually before the morning and evening meals.
Third-quarter sales for Byetta are expected to reach $175 million, about $6 million to $7 million less than Wall Street forecasters had predicted earlier this year.
0 comments - Oct 13, 2008
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.